<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>The Science ‚Äî MycoMind</title>
  <meta name="description" content="Key psilocybin studies: microdosing research, full-dose clinical trials, and preclinical animal research." />
  <link rel="preconnect" href="https://fonts.googleapis.com" />
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  <link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;600;700&display=swap" rel="stylesheet" />
  <link rel="stylesheet" href="style.css" />
</head>
<body>

  <nav class="navbar" id="navbar">
    <div class="nav-container">
      <a href="index.html" class="logo">üçÑ Myco<span>Mind</span></a>
      <button class="nav-toggle" aria-label="Toggle menu">‚ò∞</button>
      <ul class="nav-links">
        <li><a href="mental-health.html">Mental Health</a></li>
        <li><a href="physical-health.html">Physical Health</a></li>
        <li><a href="how-it-works.html">How It Works</a></li>
        <li><a href="protocols.html">Protocols</a></li>
        <li><a href="science.html" class="active">Science</a></li>
        <li><a href="my-recipe.html">My Recipe</a></li>
      </ul>
      <div class="lang-switch">
        <a href="science.html" class="active-lang">EN</a>
        <a href="es/science.html">ES</a>
      </div>
    </div>
  </nav>


  <section class="section">
    <div class="container">
      <h3 class="table-heading">Microdosing Studies</h3>
      <div class="table-wrapper">
        <table>
          <thead>
            <tr><th>Study</th><th>Year</th><th>Key Finding</th></tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Rootman et al.</strong><br /><em>Scientific Reports</em></td>
              <td>2022</td>
              <td>Largest prospective study (n=1,133). Small-to-medium improvements in mood, depression, anxiety, stress. Psychomotor gains in 55+ adults. Stamets Stack boosted motor performance.</td>
            </tr>
            <tr>
              <td><strong>Anderson et al.</strong><br /><em>Harm Reduction Journal</em></td>
              <td>2019</td>
              <td>Codebook from 278 microdosers. Top benefit: mood (26.6%), focus (14.8%). Top challenge: discomfort (18%), anxiety (6.7%).</td>
            </tr>
            <tr>
              <td><strong>Dressler, Bright &amp; Polito</strong><br /><em>J. Psychedelic Studies</em></td>
              <td>2021</td>
              <td>Increased conscientiousness and emotional insight in prospective psilocybin microdosers.</td>
            </tr>
            <tr>
              <td><strong>Polito &amp; Liknaitzky</strong><br /><em>Systematic Review</em></td>
              <td>2022</td>
              <td>Comprehensive review highlighting importance of separating pharmacological effects from expectancy/placebo.</td>
            </tr>
          </tbody>
        </table>
      </div>

      <h3 class="table-heading">Full-Dose Clinical Trials</h3>
      <div class="table-wrapper">
        <table>
          <thead>
            <tr><th>Study</th><th>Year</th><th>Key Finding</th></tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Haikazian et al.</strong><br /><em>Psychiatry Research</em></td>
              <td>2023</td>
              <td>Meta-analysis: substantial depression reductions for MDD and TRD with increased remission rates.</td>
            </tr>
            <tr>
              <td><strong>Siegel et al.</strong><br /><em>Nature</em></td>
              <td>2024</td>
              <td>Psilocybin "desynchronizes the brain" ‚Äî increases neural entropy, enabling more flexible mental states.</td>
            </tr>
            <tr>
              <td><strong>Carhart-Harris et al.</strong><br /><em>Scientific Reports</em></td>
              <td>2017</td>
              <td>fMRI: psilocybin reduces Default Mode Network activity in TRD. Reconnection correlates with improvement.</td>
            </tr>
            <tr>
              <td><strong>Griffiths et al.</strong><br /><em>Johns Hopkins</em></td>
              <td>2006‚Äì08</td>
              <td>Single dose produced mystical experiences rated among top 5 life events. 79% reported increased well-being at 2+ months.</td>
            </tr>
            <tr>
              <td><strong>Kraehenmann et al.</strong><br /><em>Biological Psychiatry</em></td>
              <td>2015</td>
              <td>Decreased amygdala reactivity correlates with enhanced positive mood in healthy volunteers.</td>
            </tr>
            <tr>
              <td><strong>King's College London</strong></td>
              <td>2024</td>
              <td>Largest controlled safety study: no serious adverse effects at clinical doses.</td>
            </tr>
          </tbody>
        </table>
      </div>

      <h3 class="table-heading">Preclinical &amp; Animal Research</h3>
      <div class="table-wrapper">
        <table>
          <thead>
            <tr><th>Area</th><th>Finding</th></tr>
          </thead>
          <tbody>
            <tr>
              <td><strong>Neurogenesis</strong></td>
              <td>Psilocybin promotes new neural connections and enhances synaptic plasticity in rodent models.</td>
            </tr>
            <tr>
              <td><strong>Anti-Inflammation</strong></td>
              <td>5-HT2A agonists reduce TNF-alpha-mediated inflammation at sub-hallucinogenic doses in mice (Nichols et al., 2017).</td>
            </tr>
            <tr>
              <td><strong>Alzheimer's</strong></td>
              <td>Psilocybin studied in preclinical Alzheimer's models for anti-inflammatory and neuroplastic effects.</td>
            </tr>
            <tr>
              <td><strong>Lion's Mane Synergy</strong></td>
              <td><em>Hericium erinaceus</em> promotes nerve growth factor (NGF) and neurogenesis in animal models ‚Äî rationale for "stacking."</td>
            </tr>
            <tr>
              <td><strong>Safety</strong></td>
              <td>No significant organ toxicity in chronic rodent studies. Lowest-harm recreational substance in comparative assessments.</td>
            </tr>
          </tbody>
        </table>
      </div>
    </div>
  </section>

  <section class="page-sources">
    <div class="container">
      <h3>Sources</h3>
      <ol class="references-list">
        <li>Rootman JM, et al. (2022). <em>Scientific Reports</em>, 12:11091. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246852/" target="_blank" rel="noopener">PMC9246852</a></li>
        <li>Anderson T, et al. (2019). <em>Harm Reduction Journal</em>, 16(1):43. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883" target="_blank" rel="noopener">PMC6617883</a></li>
        <li>Dressler HM, Bright SJ, Polito V (2021). <em>J. Psychedelic Studies</em>, 5(1):9‚Äì16.</li>
        <li>Haikazian S, et al. (2023). <em>Psychiatry Research</em>, 329:115531.</li>
        <li>Siegel JS, et al. (2024). <em>Nature</em>, 632:131‚Äì138. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291293" target="_blank" rel="noopener">PMC11291293</a></li>
        <li>Carhart-Harris RL, et al. (2017). <em>Scientific Reports</em>, 7:13187. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640601" target="_blank" rel="noopener">PMC5640601</a></li>
        <li>Griffiths RR, et al. (2006/2008). Johns Hopkins University.</li>
        <li>Kraehenmann R, et al. (2015). <em>Biological Psychiatry</em>, 78(8):572‚Äì581.</li>
        <li>Nichols DE, et al. (2017). Anti-inflammatory effects via 5-HT2A agonism.</li>
        <li>Polito V &amp; Liknaitzky P (2022). Systematic review of psychedelic microdosing.</li>
        <li>van Amsterdam J, et al. (2010). <em>Lancet</em>.</li>
      </ol>
    </div>
  </section>

  <footer class="footer">
    <div class="container">
      <div class="disclaimer">
        <h4>‚öïÔ∏è Disclaimer</h4>
        <p>This content is for <strong>educational and informational purposes only</strong>. It does not constitute medical advice. Psilocybin mushrooms are controlled substances in most jurisdictions. Always consult a healthcare professional.</p>
      </div>
      <div class="footer-bottom">
        <p class="logo-footer">üçÑ Myco<span>Mind</span></p>
        <p>&copy; 2026 MycoMind. Evidence-based. Not medical advice.</p>
      </div>
    </div>
  </footer>

  <script>
    const navbar = document.getElementById('navbar');
    window.addEventListener('scroll', () => navbar.classList.toggle('scrolled', window.scrollY > 60));
    const toggle = document.querySelector('.nav-toggle');
    const links = document.querySelector('.nav-links');
    toggle.addEventListener('click', () => links.classList.toggle('open'));
    document.querySelectorAll('.nav-links a').forEach(l => l.addEventListener('click', () => links.classList.remove('open')));
  </script>
</body>
</html>
